Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

BioMarin Pharmaceutical

NEW YORK, NY / ACCESSWIRE / November 8, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BMRN, AMRN and RECAF

Honest Co

NEW YORK, NY / ACCESSWIRE / November 7, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HNST, BMRN and AMRN

NEW YORK, Nov. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021, inclusive (the "Class Period") of the important December 23, 2021 lead plaintiff deadline. SO WHAT: If you purchased Amarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Amarin Corporation plc Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMRN

Los Angeles, California--(Newsfile Corp. - November 5, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amarin Corporation, plc ("Amarin" or "the Company") (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 5, 2018, and June 21, 2021, inclusive...

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Amarin Corporation, plc and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - November 4, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amarin Corporation, plc ("Amarin" or "the Company") (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 5, 2018, and June 21, 2021, inclusive...

INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Amarin Corporation, plc and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 4, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: BMRN AMRN RECAF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Q3 2021 Results - Earnings Call Transcript

Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

Camber Energy

NEW YORK, NY / ACCESSWIRE / November 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for AMRN, RECAF and CEI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Amarin between December 5, 2018 and June 21, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/amrn. Thi

AMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Amarin Corporation plc Investors of Class Action and Lead Plaintiff Deadline: December 20, 2021

Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022

Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update

Hoegh LNG Partners

NEW YORK, NY / ACCESSWIRE / November 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: BMRN AMRN HMLP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

New York, New York--(Newsfile Corp. - November 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court...

Rosen, Global Investor Counsel, Encourages Amarin Corporation plc Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMRN

SAN DIEGO--(BUSINESS WIRE)---- $AMRN #investment--Amarin Corporation plc (AMRN) Misstated the Impact Pending Patent Litigation Would Have on the Company's Future Prospects

SHAREHOLDER ALERT: Robbins LLP Reminds Investors that Amarin Corporation plc (AMRN) is Being Sued for Misleading Shareholders

Boston, Massachusetts--(Newsfile Corp. - November 1, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Amarin Corporation plc (NASDAQ: AMRN). The case is currently in the lead plaintiff stage. Investors who purchased AMRN securities between December 5, 2018 and June 21, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Amarin for more information. Investors may also email investors@tenlaw.com...

AMRN Investor Alert: Shareholder Lawsuit Filed

AppHarvest

NEW YORK, NY / ACCESSWIRE / October 31, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of APPH, BMRN and AMRN

Boston Beer Company

NEW YORK, NY / ACCESSWIRE / October 29, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding a possible Lead Plaintiff appointment.

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SAM, BMRN and AMRN

NEW YORK, Oct. 28, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amarin Corporation plc Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AMRN

LOS ANGELES--(BUSINESS WIRE)---- $AMRN #investors--The Law Offices of Frank R. Cruz Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $AMRN #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) investors concerning the Company's possible violations of federal securities laws. On March 30, 2020, Amarin announced that “the United States District Court for the District of Nevada[] rul[ed] in favor of the generic companies in the company's patent litigation against two filers of abbreviated new drug applications, or ANDAs,

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

SAN DIEGO, Calif.--(BUSINESS WIRE)---- $AMRN #Vascepa--Amarin Corporation plc (AMNR) Misled the Public Regarding the Impact Pending Patent Litigation Would Have on the Company's Future Prospects

SHAREHOLDER ALERT: Robbins LLP Announces that Amarin Corporation plc (AMRN) is Being Sued for Misleading Shareholders

NEW YORK, NY / ACCESSWIRE / October 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: APPH AMRN RECAF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

LOS ANGELES--(BUSINESS WIRE)---- $AMRN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Amarin investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amarin Corporation plc (AMRN) on Behalf of Investors

Waterdrop

NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.

LAWSUITS FILED AGAINST WDH, HNST and AMRN - Jakubowitz Law Pursues Shareholders Claims

SAN DIEGO, Oct. 26, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers of Amarin Corporation plc (NASDAQ: AMRN) securities between December 5, 2018 and June 21, 2021, inclusive (the "Class Period") have until December 23, 2021 to seek appointment as lead plaintiff in Dang v. Amarin Corporation plc, No.

News for Amarin Corporation Plc Stock (AMRN)